EID Parry Q2: Consolidated PAT Falls ~40% YoY to ₹253 Cr as Margins Compress
PAT -40.42% YoY · revenue -3.48% · margins compressing · beat vs street
₹11,213.33 Cr
-3.48% YoY
₹252.86 Cr
-40.42% YoY
2.25%
-4.3pp YoY
₹14.2
EID Parry's consolidated (primary) PAT attributable to owners fell ~40% YoY to ₹252.86 Cr from ₹424.41 Cr in Q2 FY26, even as group revenue dipped ~3.5% YoY to ₹11,219.70 Cr — a second straight quarter of YoY earnings weakness, as flagged in our pre-result preview. Sequentially both metrics jumped sharply (PAT +79% QoQ, revenue +24% QoQ) on the seasonal Kharif-season ramp in the Coromandel nutrient and allied business (₹9,042 Cr segment revenue, ₹745.90 Cr segment PBIT) — this QoQ strength is a seasonality artifact typical of the agri-input cycle, not a turnaround signal, and the YoY decline remains the operative story. No exceptional items hit either statement this quarter, so both prints are clean like-for-like comparisons.
Q2 FY-2027 vs prior quarters
Margins compressed on a YoY basis: net margin (owners'-PAT basis) fell to ~2.25% from ~3.65% a year ago, though it improved from ~1.57% in Q1 FY27. Our own EBITDA-margin estimate from the filing works out to ~8.8%, down from ~10.3% YoY but up from Q1's ~8.3%. Beyond the dominant nutrient/crop-protection businesses, two standalone drag segments remain relevant: Consumer Products (CPG), whose loss widened to ₹24.48 Cr this quarter from ₹11.98 Cr in Q1 FY27 (though narrower than ₹26.93 Cr a year ago), and Nutraceuticals, which posted a ~10.9% margin (₹7.67 Cr profit on ₹70.10 Cr revenue) — below the 12-15% steady-state band management flagged on the August 2026 call.
The stock went into the print at ₹658.55, down 4.8% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters.
CPG quarterly breakeven in 4-5 quarters (accelerated from 6-8Q prior). Nutra EBITDA margin 12-15% steady-state. Jaggery plant online in 6 months (₹100Cr capacity). No FY27 aggregate revenue/PAT guidance; ethanol blending to remain at 20%.
— This quarter: missed
There is no verified external analyst consensus for this specific quarter (coverage is thin — the preview noted a single-analyst Buy rating with a recently cut FY27 target), so the cleanest yardstick is our own pre-result preview, which modeled consolidated revenue of ₹8,900-9,100 Cr, PAT of ₹100-140 Cr and an 8-9% EBITDA margin. The actual print beat that range decisively on revenue (+23-26% above the top end) and PAT (nearly double the top end), while the margin assumption landed almost exactly in the money (~8.8% vs 8-9% guided) — indicating the preview had under-anchored growth to Q1's seasonally soft base rather than Q2's agri-season strength. Against management's own prior framing from the last call: Nutraceuticals remains below its targeted margin band, and CPG shows no sequential progress toward the 4-5-quarter breakeven path (the loss widened, not narrowed, versus Q1); management gave no formal FY27 revenue/PAT guidance, consistent with the prior call, so that specific angle is unresolved on record. No management press release text was available to quote for this filing. Subsequent to the quarter, the Board approved a slump sale of the Sivagangai Distillery Unit on a going-concern basis (Nov 13, 2026), a non-adjusting event with no impact on these numbers; separately, standalone's year-ago quarter carried a ₹352.23 Cr one-off impairment tied to the Parry Sugars Refinery India (PSRIPL) closure that is absent this quarter and absent at the consolidated level throughout — which is why standalone's YoY narrative (loss narrowing to ₹22.49 Cr from ₹285.62 Cr) looks far better than the consolidated one.
W1
CPG breakeven path — guided 4-5 quarters from the Aug 2026 call; loss widened to ₹24.48 Cr this quarter from ₹11.98 Cr in Q1 FY27, the opposite of the needed direction
W2
Nutraceuticals EBITDA margin — currently ~10.9% (₹7.67 Cr/₹70.10 Cr), below the 12-15% steady-state band management targets
W3
Jaggery plant (₹100 Cr capacity) commissioning — guided ~6 months from the August 2026 call (around February 2027); no update given this quarter
Consolidated PAT shown (₹252.86 Cr) is attributable to owners of the company (ties to EPS 14.20 and public reporting) — total Group PAT incl. non-controlling interest (Coromandel International minority) is ₹479.43 Cr, which is the basis our internal comparison series (₹311.50 Cr/₹766.16 Cr) appears to use; growth rates here are computed on the owners'-PAT basis for consistency with the headline figure. No exceptional items this quarter at standalone or consolidated level; year-ago standalone quarter carried a ₹352.23 Cr one-off impairment (PSRIPL closure) absent from consolidated throughout.
Informational and educational content only. Not investment advice.